NovaGo Therapeutics focuses on two regeneration promoting therapeutics aimed at restoring nerve fibre connections in acute spinal cord injury(SCI) and retinal vasculature in diabetic retinopathy(DR), Ph1b clinical trial for SCI was started in Dec 2024. Ph1b studies in DR are planned for end 2025.